Clinical Trial

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
Protocol Amendment History 10 changes
notable Trial sites expanded: 187 -> 191 locations 2026-08-15
notable Trial sites expanded: 183 -> 186 locations 2026-07-28
notable Trial sites expanded: 178 -> 181 locations 2026-07-11
notable Trial sites expanded: 174 -> 178 locations 2026-06-30
notable Trial sites expanded: 164 -> 167 locations 2026-05-09
notable Trial sites expanded: 159 -> 164 locations 2026-05-01
notable Trial sites expanded: 155 -> 159 locations 2026-04-17
notable Trial sites expanded: 152 -> 155 locations 2026-04-14
notable Trial sites expanded: 140 -> 152 locations 2026-04-03
notable Trial sites expanded: 134 -> 140 locations 2026-03-27
Trial Details
NCT Number NCT06824467
Lead Sponsor Merck Sharp & Dohme LLC
Collaborators: European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Conditions Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Enrollment 770 participants
Start Date 2025-04-09
Primary Completion 2029-04-27 (estimated)
Study Completion 2032-11-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-14